# Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

> **NCT05320640** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed/Refractory Non-Hodgkin Lymphoma
- Advanced Solid Tumors

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Decitabine
- **DRUG:** Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）

## Key facts

- **NCT ID:** NCT05320640
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-30
- **Primary completion:** 2024-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320640, "Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05320640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*